- Home
- REI vs TRDA Comparison
REI vs TRDA Comparison
Compare REI & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REI
- TRDA
- Stock Information
- Founded
- REI 2004
- TRDA 2016
- Country
- REI United States
- TRDA United States
- Employees
- REI 115
- TRDA N/A
- Industry
- REI Oil & Gas Production
- TRDA Biotechnology: Pharmaceutical Preparations
- Sector
- REI Energy
- TRDA Health Care
- Exchange
- REI Nasdaq
- TRDA Nasdaq
- Market Cap
- REI 206.5M
- TRDA 235.4M
- IPO Year
- REI N/A
- TRDA 2021
- Fundamental
- Price
- REI $1.00
- TRDA $7.31
- Analyst Decision
- REI
- TRDA Strong Buy
- Analyst Count
- REI 0
- TRDA 3
- Target Price
- REI N/A
- TRDA $25.67
- AVG Volume (30 Days)
- REI 2.6M
- TRDA 183.0K
- Earning Date
- REI 11-06-2025
- TRDA 11-06-2025
- Dividend Yield
- REI N/A
- TRDA N/A
- EPS Growth
- REI N/A
- TRDA N/A
- EPS
- REI 0.35
- TRDA N/A
- Revenue
- REI $318,900,835.00
- TRDA $79,476,000.00
- Revenue This Year
- REI N/A
- TRDA N/A
- Revenue Next Year
- REI $9.58
- TRDA N/A
- P/E Ratio
- REI $2.90
- TRDA N/A
- Revenue Growth
- REI N/A
- TRDA N/A
- 52 Week Low
- REI $0.72
- TRDA $4.93
- 52 Week High
- REI $1.77
- TRDA $21.79
- Technical
- Relative Strength Index (RSI)
- REI 48.34
- TRDA 69.18
- Support Level
- REI $0.91
- TRDA $5.70
- Resistance Level
- REI $1.05
- TRDA $6.49
- Average True Range (ATR)
- REI 0.05
- TRDA 0.47
- MACD
- REI -0.01
- TRDA 0.09
- Stochastic Oscillator
- REI 35.97
- TRDA 90.67
About REI Ring Energy Inc.
Ring Energy Inc is an independent exploration and production company based in The Woodlands, Texas and is engaged in oil and natural gas development, production, acquisition, and exploration activities currently focused in the Permian Basin of Texas. The drilling operations of the company target the oil and liquid rich producing formations in the Northwest Shelf, the Central Basin Platform and the Delaware Basin all of which are part of the Permian Basin in Texas.
About TRDA Entrada Therapeutics Inc.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.